Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
6.75
+0.19 (2.90%)
At close: Aug 4, 2025, 4:00 PM
6.75
0.00 (0.00%)
Pre-market: Aug 5, 2025, 4:33 AM EDT

Company Description

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally.

The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.

It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc.
Novavax logo
CountryUnited States
Founded1987
IPO DateDec 5, 1995
IndustryBiotechnology
SectorHealthcare
Employees952
CEOJohn Jacobs

Contact Details

Address:
700 Quince Orchard Road
Gaithersburg, Maryland 20878
United States
Phone240 268 2000
Websitenovavax.com

Stock Details

Ticker SymbolNVAX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001000694
CUSIP Number670002401
ISIN NumberUS6700024010
Employer ID22-2816046
SIC Code2836

Key Executives

NamePosition
John Charles Jacobs M.B.A.President, Chief Executive Officer and Director
James Patrick Kelly C.F.A.Executive Vice President, Chief Financial Officer and Treasurer
Mark J. Casey Esq.Executive Vice President, Chief Legal Officer and Corporate Secretary
Elaine O'HaraExecutive Vice President and Chief Strategy Officer
Richard P. CrowleyExecutive Vice President and Chief Operating Officer
Troy Morgan Esq., J.D.Senior Vice President, Deputy General Counsel and Chief Compliance Officer
Erika S. TrahanAssociate Director of Investor and Public Relations
Ian J. WatkinsExecutive Vice President and Chief Human Resources Officer
Silvia Taylor M.B.A.Executive Vice President and Chief Corporate Affairs and Advocacy Officer
Dr. Henrietta Ukwu FACP FRAPS, M.D.Executive Vice President and Chief Regulatory Officer

Latest SEC Filings

DateTypeTitle
Jun 24, 20258-KCurrent Report
Jun 11, 20258-KCurrent Report
May 27, 20258-KCurrent Report
May 19, 2025144Filing
May 19, 20258-KCurrent Report
May 8, 20258-KCurrent Report
May 8, 202510-QQuarterly Report
May 5, 20258-KCurrent Report
Apr 30, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2025ARSFiling